Accumulation of boron in human malignant glioma cells in vitro is cell type dependent.
It has been shown that human malignant glioma tumours consist of several subpopulations of tumour cells. Due to heterogeneity and different degrees of vascularisation cell subpopulations possess varying resistance to chemo- or radiation therapy. Therefore, therapy is dependent on the ability to specifically target a tumour cell. Boron neutron capture therapy (BNCT) is a bimodal method, in radiation therapy, taking advantage of the ability of the stable isotope boron-10 to capture neutrons. It results in disintegration products depositing large amounts of energy within a short length, approximately one cell diameter. Thereby, selective irradiation of a target cell may be accomplished if a sufficient amount of boron has been accumulated and hence the cell-associated boron concentration is of critical importance. The accumulation of boron, boronophenylalanine (BPA), was investigated in two human glioma cell subpopulations and a human fibroblast cell line in vitro. The cells were incubated at low boron concentrations (0-5 microg B/ml). Oil filtration was then used for separation of extracellular and cell-associated boron. Inductively coupled plasma atomic emission spectroscopy (ICP-AES) was used for boron determination. Significant (P < 0.05) differences in accumulation ratio (relation between cell-associated and extracellular boron concentration) between human malignant glioma cell lines were found. Human fibroblasts, used to represent normal cells, showed a growth-dependent uptake and a lower accumulation ratio than the glioma cells. Our findings indicate that BPA concentration, incubation time and differences in boron uptake between cell subpopulations should be considered in BNCT.
Division of Cell Biology, Department of Biomedicine and Surgery, Faculty of Health Sciences, Linköping University, Sweden.
Maria
M
Dahlström
Jacek
J
Capala
Peter
P
Lindström
Ake
A
Wasteson
Annelie
A
Lindström
D001880:Boranes / Q000493:pharmacokinetics; D001895:Boron / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy*; D002460:Cell Line; D045744:Cell Line, Tumor; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D005909:Glioblastoma / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D005910:Glioma / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D001880:Boranes; C447034:boronophenylalaninol; D010649:Phenylalanine; D001895:Boron